General | ||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||
Comparison | ||||||||||||||||||||||||||||
|
Date | For | Estimate | Reported | Surprise | surprise % |
---|---|---|---|---|---|
2024-05-14 | 2024-03 | -0.27 | -0.06 | 0.21 | 77.78% |
2024-03-21 | 2023-12 | -0.49 | -0.33 | 0.16 | 32.65% |
2024-03-21 | 2023-12 | -0.49 | N/A | N/A | N/A |
2023-11-07 | 2023-09 | -0.57 | -0.56 | 0.01 | 1.75% |
2023-11-07 | 2023-09 | -0.57 | N/A | N/A | N/A |
2023-08-11 | 2023-06 | -0.66 | N/A | N/A | N/A |
Date | Firm | Action | From | To |
---|---|---|---|---|
2023-09-04 | RBC Capital | Upgrade | Outperform | |
2023-07-30 | EF Hutton | Upgrade | Buy | |
2023-03-22 | Credit Suisse | Upgrade | Outperform | |
2021-11-01 | Credit Suisse | Upgrade | Outperform | |
2021-11-01 | Jefferies | Upgrade | Buy | |
2021-11-01 | B of A Securities | Upgrade | Neutral |
Date | Name | Relation | Quantity | Description |
---|---|---|---|---|
2023-03-23 | CIVIK THOMAS | Director | 221.89K | Stock Award(Grant) |
2024-03-25 | CLINE DARREN S | Director | 251.41K | Stock Award(Grant) |
2024-03-25 | CONNEALY PAMELA ANN | Chief Operating Officer | 1.11M | Stock Award(Grant) |
2024-03-25 | DUPONT JAKOB | Director | 38.74K | Stock Award(Grant) |
2024-03-25 | FLAVIN JOHN L. | Director | 413.02K | Stock Award(Grant) |
2024-03-25 | HUMPHREY RACHEL W M.D. | Director | 96.81K | Stock Award(Grant) |
Report Date | Organization | Position | Value | Percentage |
---|---|---|---|---|
2023-06-29 | Laurion Capital Management, LP | 3.17M | 8.12M | 8.02% |
2023-06-29 | Tang Capital Management, LLC | 1.79M | 4.58M | 4.52% |
2023-06-29 | Vanguard Group Inc | 1.10M | 2.81M | 2.77% |
2023-06-29 | Tekla Capital Management LLCC. | 708.30K | 1.81M | 1.79% |
2023-06-29 | HHLR Advisors, LTD | 382.61K | 979.47K | 0.97% |
2023-06-29 | Bridgeway Capital Management, Inc. | 286.20K | 732.66K | 0.72% |
Report Date | Organization | Position | Value | Percentage |
---|---|---|---|---|
2023-06-29 | Vanguard Total Stock Market Index Fund | 748.92K | 1.92M | 1.89% |
2023-06-29 | Tekla Healthcare Investors | 481.65K | 1.23M | 1.22% |
2023-06-29 | Vanguard Extended Market Index Fund | 330.18K | 845.26K | 0.84% |
2023-06-29 | Tekla Life Sciences Investors | 226.66K | 580.24K | 0.57% |
2023-06-29 | Bridgeway Funds Inc-Ultra Small Company Market Fund | 170.30K | 435.96K | 0.43% |
2023-05-30 | Fidelity Extended Market Index Fund | 128.66K | 414.30K | 0.33% |
True but they will be flat for awhile until new news comes out and drug gets closer to market
Sold at $6.20…happy with my $6k profit for a month
@Jim why do you like BLUE?? That stock is garbage! I liked it too until I lost a ton on it. Look at the chart. ️
Let’s GOOOOO $5
Sitting on 3k shares at $3.45…holding long!! Eating for that $8
It’s the exact same chart as Friday
Pure manipulation. Gonna go to $3 then pump up
$PYXS Not sure if anyone saw it earlier but it did touch 5.10ish a few minutes after hours.
The only think pYXS is doing , is not curing cancer